A new study has found that for many people, the immunization shots they get from Pfizer are not enough to protect them from getting sick. If you have been wondering when your booster will come, this is a great article about what might be happening and how you can protect yourself.
In what sounds like a joke, a vaccine designed by Big Pharma meant to protect seniors from shingles was found to leave many people who got it vulnerable. Many of those people ended up needing hospitalization due to the illness because they were not protected by the vaccine.
Shingles is a dangerous and painful skin condition. A recent study found that people who had received the vaccine were just as likely to get shingles as those who had not been vaccinated, though they may have less severe cases. This means there is no point in getting the shots if you are trying to prevent the condition.
The vaccine, which is marketed by Pfizer, is called Shingrix. It was found to work only in half of the people that took it. For those who were protected from shingles, their cases were less severe than if they had not gotten any protection at all. The results might have been different had the vaccine protected more people. The numbers are not available, however.
The researchers were surprised by the outcome of their study because they had expected the vaccine to work well since it is derived from a similar one that has been shown to protect against shingles in older adults. That drug, Zostavax, was effective for about 70% of adults, and they believed Shingrix would perform even better than its predecessor.
It involved more than 38,000 participants aged 50 or older who were given the vaccine to either prevent shingles or see if it could reduce pain symptoms once they had gotten sick. No one believed the vaccine would not work at all.
While medical professionals and people who study vaccinations were surprised by the findings, they also say it is possible that Shingrix will perform better in younger adults. This means researchers might need to do additional studies on older patients until they figure out how well it works for them.
So far, the Centers for Disease Control and Prevention (CDC) only recommend that people in their 50s get Shingrix. People in their 60s are also included, but they say this is because there is limited data on vaccine performance at the age.
Many experts are wondering how to develop vaccines when research shows they might not be effective enough to warrant their use. It is known that vaccines are costlier to produce than drugs. Therefore, testing them seems unnecessary when the results have shown that they might not work at all.
It should be noted that Pfizer provided funding for this study and many of the authors have ties to the company. There are also other vaccines in development by Big Pharma that could be affected by this study. One drug under development is a multi-strain vaccine that would protect against influenza, one of the most common infectious diseases. Estimates show that about 36,000 Americans die from influenza each year.
Since vaccines are usually recommended for older adults, there is a need to know how well they work so that people get the ones that are most likely to provide protection. That way, fewer people will get sick and need health care services, which means everyone benefits.
The CDC has not yet responded to the information about this vaccine. It is possible they were aware of it in advance since Pfizer provided them with a copy of the study results in advance.
There is a vaccine to prevent shingles that might not work at all, according to a recent study. The researchers found that people who took it were just as likely to get the condition as those who did not get any protection from it.